CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

CD19/BCMA 靶向 CAR-T 细胞治疗急性白血病患者抗 HLA 抗体致敏：一项初步临床研究

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Stu

B 细胞成熟抗原-CD19 双靶向 CAR-T 细胞治疗复发/难治性 AL 淀粉样变性

B -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis.

本研究评估了 B 细胞成熟抗原-CD19 双靶向 CAR-T 细胞疗法对复发/难治性 AL 型淀粉样变性患者的安全性和有效性。

早期鞘内注射地塞米松和甲氨蝶呤作为 CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征的有效方法

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell

我们的数据提示，早期给予 IDM 可能有助于快速缓解 CAR-T 细胞治疗后的重度或类固醇难治性 ICANS，这可能为这些患者的后续治疗创造机会。

复发/难治性多发性骨髓瘤患者 CAR-T 治疗后继发治疗相关急性髓系白血病且预后不良

Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.

泊马度胺提高伴髓外病变的复发/难治性多发性骨髓瘤或 B 细胞白血病/淋巴瘤 CAR-T 治疗的疗效

Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedul

病例报告：冷冻消融作为大肿块 B 细胞恶性肿瘤 CAR-T 细胞治疗前的新型桥接策略

Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease.

一种从高单核细胞计数患者中纯化并激活 T 细胞以成功制备 CAR-T (CAR-T) 细胞的简单有效方法

A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with

在本研究中，我们发现选择 CD3+ T 细胞分离培养基对于提高 T 细胞激活、转导和 CAR-T 增殖至关重要。

病例报告：CAR-T 细胞诱导的迟发性重度细胞因子释放综合征

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome.

重度 CRS 可能发生在 CAR-T 治疗后期，因为 CAR-T 细胞的再扩增具有迟发性 sCRS 的潜在风险。

C3aR 共刺激通过 Th17 扩增与记忆 T 细胞诱导增强 CAR-T 细胞疗法的抗肿瘤疗效

C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.